UK Urged To Protect R&D Tax Credits, The Lifeblood Of Biotechs

Verona Pharma is rising high with the newly-launched chronic obstructive pulmonary disease drug Ohtuvayre but its development would have been severely compromised if it had not been for government benefits, non-executive chair David Ebsworth tells Scrip.